

- 2 -

**Amendment to the Claims**

The listing of claims will replace all prior versions of claims in the application:

Claim 1 (currently amended): An isolated, non-crystalline polypeptide defined by the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6.

Claims 2-6 (cancelled).

Claim 7 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 5.

Claim 8 (previously presented): The polypeptide of claim 1, defined by the amino acid sequence set forth in SEQ ID NO: 6.

Claim 9 (previously presented): An isolated, non-crystalline polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 6 except that the polypeptide has a single amino acid substitution at Asp 73 or Arg 81, wherein the substitution is a nonpolar amino acid.

Claim 10 (cancelled)

Claim 11 (previously presented): A composition, comprising a protein crystal of SEQ ID NO: 17, wherein the crystal has space group P21 and unit cell dimensions of  $a=34.8 \text{ \AA}$ ,  $b=67.1 \text{ \AA}$ ,  $c=58.4 \text{ \AA}$ ,  $\alpha=90^\circ$ ,  $\beta=101.3^\circ$ ,  $\gamma=90^\circ$  with two molecules of SEQ ID NO:17 in the asymmetric unit.

Claims 12-20 (cancelled).

Claim 21 (previously presented): An isolated, non-crystalline polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 6, except that the polypeptide has a single amino acid substitution at Asp 73 or Arg 81, wherein the substitution at Asp 73 is lysine or arginine and the substitution at Arg 81 is glutamic acid or aspartic acid.

- 3 -

Claim 22 (previously presented): An isolated, non-crystalline polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 5, except that the polypeptide has a substitution of the amino acids at positions 255-258 with SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, or 14.